Omeros Corporation - Common Stock (NQ:OMER)

19.83 +0.71 (+3.71%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 Next >

Omeros Corporation Reports Second Quarter 2026 Financial Results

August 12, 2026

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

August 10, 2026

From Omeros Corporation

Via Business Wire

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

August 03, 2026

From Omeros Corporation

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

July 14, 2026

From Pomerantz LLP

Via GlobeNewswire

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

July 08, 2026

From Schall Law

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

July 07, 2026

From Pomerantz LLP

Via GlobeNewswire

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

July 06, 2026

From The Schall Law Firm

Via Business Wire

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

June 26, 2026

From Omeros Corporation

Via Business Wire

Omeros Announces Webcast Details for Annual Meeting of Shareholders

June 15, 2026

From Omeros Corporation

Via Business Wire

Omeros Corporation Reports First Quarter 2026 Financial Results

May 13, 2026

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

May 11, 2026

From Omeros Corporation

Via Business Wire

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

April 20, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

April 16, 2026

From Omeros Corporation

Via Business Wire

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

March 31, 2026

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

March 26, 2026

From Omeros Corporation

Via Business Wire

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

March 21, 2026

From Omeros Corporation

Via Business Wire

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

February 17, 2026

From Omeros Corporation

Via Business Wire

Omeros Announces First Commercial Sales of YARTEMLEA®

January 27, 2026

From Omeros Corporation

Via Business Wire

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

December 26, 2025

From Omeros Corporation

Via Business Wire

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

December 24, 2025

From Omeros Corporation

Via Business Wire

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

December 01, 2025

From Omeros Corporation

Via Business Wire

Omeros Corporation Reports Third Quarter 2025 Financial Results

November 13, 2025

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

November 11, 2025

From Omeros Corporation

Via Business Wire

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

October 16, 2025

From Omeros Corporation

Via Business Wire

The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside)

October 15, 2025

Via AB Newswire

Topics Artificial Intelligence Cannabis

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

September 02, 2025

From Omeros Corporation

Via Business Wire

Omeros Corporation Reports Second Quarter 2025 Financial Results

August 14, 2025

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

August 11, 2025

From Omeros Corporation

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.